pharmacie et médicaments – Non-autorisation de la délivrance des nouveaux médicaments contre le myélome

This written question asks about the non-approval of new drugs for treating myeloma, a type of blood cancer. It seeks clarification on the reasons behind this decision and its impact on patients. The question affects patients with myeloma, their doctors, and pharmaceutical companies involved in developing these treatments. It highlights concerns about access to innovative therapies.